Clinical Report: Call to Increase Cataract Payment Rates
Overview
The Outpatient Ophthalmic Surgery Society (OOSS) has submitted comments regarding a proposed 3.5% decrease in cataract payment rates by CMS for 2027. This reduction would mark the first time in over two decades that ophthalmic ASCs have not received an increase in payment rates.
Background
Cataract surgery is the most common procedure performed in ambulatory surgery centers (ASCs), accounting for a significant portion of ASC volume and spending. The proposed cuts in Medicare reimbursement could affect ophthalmic practices.
Data Highlights
No numerical data provided in the source material.
Key Findings
- The proposed 3.5% decrease in cataract payments by CMS would be unprecedented in over 20 years.
- OOSS, along with other eye organizations, is advocating against the proposed cuts.
- Payments for ophthalmic surgeons are declining, with a 2.83% cut in Medicare reimbursements expected in 2025.
- Many commercial payers base their reimbursement on Medicare rates, amplifying the impact of cuts.
- Quality reporting programs track cataract outcomes, emphasizing the importance of maintaining adequate reimbursement for quality care.
Clinical Implications
The proposed cuts in cataract payment rates may lead to reduced access to cataract surgery for patients.
Conclusion
The ongoing trend of declining cataract payment rates requires attention from the ophthalmic community.
Related Resources & Content
- OOSS, Washington Watch, 2023 -- Call to Increase Cataract Payment Rates
- Parag Parekh, MD, MPA, Ophthalmology Management, 2025 -- Why Cataract Payments Keep Falling
- Ophthalmic Professional, 2019 -- Viewpoint from the Editor
- MedPAC, March 2025 Report to Congress
- World Health Organization, 2026 -- Summary of recommendations for quality of care in cataract surgery management
- ophthalmology management — QUICK HITS
- MedPAC March 2025 report to the Congress
- Summary of recommendations for quality of care in cataract surgery management
- Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial - ScienceDirect
- One in two people facing cataract blindness need access to life-changing surgery
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







